Business
GenSpera Announces Name Change to Inspyr Therapeutics
GenSpera Announces Name Change to Inspyr Therapeutics.
About this update from Rebus Hldgs Inc.
[{"type":"text","content":"\n \n GenSpera, Inc. (OTC/QB: GNSZ), a clinical-stage biotechnology company \n developing a novel prodrug therapeutic for the treatment of cancer, \n announces that it will change its corporate name to Inspyr Therapeutics, \n Inc. and will begin trading on OTC/QB under the ticker symbol NSPX \n effective August 2, 2016. The Company will also unveil a new corporate \n website at www.inspyrtx.com.\n \n \n “The changing of our corporate name is a first step in a number of \n upcoming actions that will define our path forward and our focus on \n building shareholder value,” said Peter E. Grebow, Ph.D., Interim \n Chairman. “Our new corporate name, Inspyr Therapeutics, reflects the \n significant potential we see with the novel prodrug mipsagargin and our \n Company’s future potential.”\n \n \n About Inspyr Therapeutics\n \n \n Inspyr Therapeutics, Inc. (formerly known as GenSpera, Inc.) is \n developing a novel technology platform that combines a powerful \n cytotoxin (thapsigargin) with a patented prodrug delivery system that \n targets the release of drugs within solid tumors without the side \n effects of chemotherapeutic agents. Mipsagargin, its lead drug \n candidate, has been studied in a Phase 2 clinical trial in patients with \n hepatocellular carcinoma (liver cancer) and has been granted Orphan Drug \n designation by the U.S. Food and Drug Administration (FDA) in this \n indication. Mipsagargin is being evaluated in other therapeutic areas \n within oncology. For additional information on Inspyr Therapeutics, \n visit www.inspyrtx.com\n \n \n Cautionary Statement Regarding Forward-Looking Information\n \n \n This communication may contain forward-looking statements. Investors are \n cautioned that statements in this document regarding potential \n applications of GenSpera’s technologies or the future prospects of the \n company constitute forward-looking statements that involve risks and \n uncertainties, including, without limitation, risks inherent in the \n development and commercialization of potential products, uncertainty of \n clinical trial results or regulatory approvals or clearances, need for \n future capital, dependence upon collaborators and maintenance of our \n intellectual property rights and the acceptance of GenSpera’s proposed \n therapies by the health community...